Table I.
Patient characteristics.
| Characteristic | Value |
|---|---|
| N | 120 |
| Median age, years (range) | 73 (42–92) |
| Sex, female/male | 24/96 |
| PS, 0/1/2 | 100/18/2 |
| Median body mass index, kg/m2 (range) | 23.3 (15.9–38.8) |
| Cause of HCC, HBV/HCV/Non-B,C | 23/46/51 |
| Child-Pugh class/score | |
| A (5/6) | 110 (54/56) |
| B (7/8) | 10 (7/3) |
| Median AST, U/l (range) | 34 (10–274) |
| Median ALT, U/l (range) | 24 (4–208) |
| Median serum albumin, g/dl (range) | 3.6 (2.4–4.6) |
| Median total bilirubin, mg/dl (range) | 0.8 (0.3–2.0) |
| Median ALBI score (range) | −2.27 |
| (−3.19 to −1.04) | |
| mALBI grade, 1/2a/2b/3 | 29/33/57/1 |
| BCLC stage, B/C | 67/53 |
| Macrovascular invasion, yes/no | 22/98 |
| Extrahepatic spread, yes/no | 36/84 |
| Median AFP, ng/ml (range) | 56.5 |
| (1.6–2580,000.0) | |
| Treatment line | |
| First-line | 44 |
| Later-line (2nd/3rd/4th/5th/6th/7th) | 76 |
| (36/18/11/5/5/1) | |
| Pre-ICI treatment, yes/no | 67/53 |
| HIMALAYA trial exclusion criteria, yes/no | 82/38 |
| Later-line | 65 |
| Later-line + Vp 4 | 3 |
| Later-line + Child-Pugh class B | 6 |
| Later-line + Increased AST or ALT | 2 |
| Child-Pugh class B | 4 |
| Increased AST or ALT | 2 |
| Median follow-up duration, months (range) | 5.6 (1.0–9.0) |
PS, performance status; HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; mALBI, modified albumin-bilirubin; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; ICI, immune checkpoint inhibitor.